Are the Shorts Wrong About Questcor?

Questcor is one of the most shorted health-care stocks on the market. Despite the company's profitability and strong cash flow, shares have taken a big hit as concerns arose regarding its top selling drug, Acthar. In this video, Motley Fool health-care analyst David Williamson reviews the bear case against Questcor and whether they are likely right in their assumptions.

Questcor is one of the most debated names in all of biotech. Acthar is growing at a torrid pace -- and minting money in the process. However, recent events have created significant doubts about Questcor's future. Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand-new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.

The article Are the Shorts Wrong About Questcor? originally appeared on Fool.com.

Brenton Flynn, David Williamson, and The Motley Fool have no positions in the stocks mentioned above. Follow David on Twitter @MotleyDavid. Motley Fool newsletter services recommend UnitedHealth Group. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.